|
|
Post by akemp3000 on Sept 18, 2016 11:36:46 GMT -5
This has been such a long time coming following 8,000 trial participants over ten years, delayed action by the FDA who mandated antiquated trial protocols be used, a failed Sanofi partnership, relentless bashing, market manipulation and the passing of the great Al Mann. Fortunately there's a reason Afrezza and MNKD have survived through all this and it's all based on superior science. We now know Afrezza is the greatest advancement in a generation for treating the world's largest disease but now it's time that the world learns this as well. It appears Matt, Mike and team have made a monumental effort to resurrect knowledge and scripts with the 2.0 launch that began slowly in July. At the time, they said we should begin seeing a rise in scripts in the September and October time period. Now we're here and the next month is going to provide the answer. I remain optimistic that the forthcoming success will be comparably as great as the pain of the past has been. Diabetics first and then longs deserve the reward that has been a long time coming.
|
|
|
|
Post by anthony7 on Sept 18, 2016 13:31:28 GMT -5
Here Here! I need Afrezza for a better life. I am going to post a new topic as to what has been the representative advertising expenditure for direct to consumer advertising for a $2 billion new drug?
|
|
|
|
Post by surplusvalue on Sept 18, 2016 14:29:22 GMT -5
This has been such a long time coming following 8,000 trial participants over ten years, delayed action by the FDA who mandated antiquated trial protocols be used, a failed Sanofi partnership, relentless bashing, market manipulation and the passing of the great Al Mann. Fortunately there's a reason Afrezza and MNKD have survived through all this and it's all based on superior science. We now know Afrezza is the greatest advancement in a generation for treating the world's largest disease but now it's time that the world learns this as well. It appears Matt, Mike and team have made a monumental effort to resurrect knowledge and scripts with the 2.0 launch that began slowly in July. At the time, they said we should begin seeing a rise in scripts in the September and October time period. Now we're here and the next month is going to provide the answer. I remain optimistic that the forthcoming success will be comparably as great as the pain of the past has been. Diabetics first and then longs deserve the reward that has been a long time coming. Like your enthusiasm but sorry I have to disagree. Dont see this as a binary moment at all nor do I believe that MNKD sees it that way either. I think that this will be a longer process than many of us think or are prepared for. If you are expecting to see the answer in October I think you may be setting yourself up for disappointment. October is still too early to assess script trends since the direct to patient efforts are just beginning and we just also found out that the packaging cartridge/inhaler issue will not be solved until November according to Matt. Some particular individuals may see October as a binary moment in which to decide to stay or get out which is up to them but I don't think this describes the process of what we are seeing as a whole including MNKD's timeline. |
|
|
|
Post by saxcmann on Sept 18, 2016 20:45:25 GMT -5
This has been such a long time coming following 8,000 trial participants over ten years, delayed action by the FDA who mandated antiquated trial protocols be used, a failed Sanofi partnership, relentless bashing, market manipulation and the passing of the great Al Mann. Fortunately there's a reason Afrezza and MNKD have survived through all this and it's all based on superior science. We now know Afrezza is the greatest advancement in a generation for treating the world's largest disease but now it's time that the world learns this as well. It appears Matt, Mike and team have made a monumental effort to resurrect knowledge and scripts with the 2.0 launch that began slowly in July. At the time, they said we should begin seeing a rise in scripts in the September and October time period. Now we're here and the next month is going to provide the answer. I remain optimistic that the forthcoming success will be comparably as great as the pain of the past has been. Diabetics first and then longs deserve the reward that has been a long time coming. Like your enthusiasm but sorry I have to disagree. Dont see this as a binary moment at all nor do I believe that MNKD sees it that way either. I think that this will be a longer process than many of us think or are prepared for. If you are expecting to see the answer in October I think you may be setting yourself up for disappointment. October is still too early to assess script trends since the direct to patient efforts are just beginning and we just also found out that the packaging cartridge/inhaler issue will not be solved until November according to Matt. Some particular individuals may see October as a binary moment in which to decide to stay or get out which is up to them but I don't think this describes the process of what we are seeing as a whole including MNKD's timeline. Not sure about binary moment either but I do think we'll have a significant jump in scripts in October. If we can't get NRx's above 200+ we are not trending fast enough in my opinion. 60 reps should be able to achieve 1 prescription per week from docs. |
|
|
|
Post by akemp3000 on Sept 18, 2016 22:40:24 GMT -5
Just to clarify a little better, my intent was not to mean a binary moment of absolute success or failure. I simply view October as a significant moment in time that's about to tell us which of the two directions the future is heading. I'm not expecting a dramatic increase in scripts but am looking for a significant and steady rise to begin. If and when this happens, the future will be bright and the FUD will finally be dead...IMHO.
|
|
|
|
Post by broncolife on Sept 18, 2016 23:27:05 GMT -5
akemp, can you clarify your statement on cartridge/inhaler issue. I never heard about it anywhere as of yet.
|
|
|
|
Post by jonny80s on Sept 19, 2016 6:13:10 GMT -5
I second that. What cartridge/inhaler issue?  |
|
|
|
Post by prvs on Sept 19, 2016 6:34:37 GMT -5
akemp, can you clarify your statement on cartridge/inhaler issue. I never heard about it anywhere as of yet. I read somewhere that many of the scripts when picked up didn't include inhalers, the inhalers had been packaged separately and sometimes weren't sent along with the scrip to the pharmacy. It's a left over issue from SNY. MNKD will now start including the inhalers in the same packaging as the drug. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 19, 2016 7:09:33 GMT -5
akemp, can you clarify your statement on cartridge/inhaler issue. I never heard about it anywhere as of yet. I read somewhere that many of the scripts when picked up didn't include inhalers, the inhalers had been packaged separately and sometimes weren't sent along with the scrip to the pharmacy. It's a left over issue from SNY. MNKD will now start including the inhalers in the same packaging as the drug. That was the case for samples not RX dispensed |
|
|
|
Post by gonetotown on Sept 19, 2016 8:28:57 GMT -5
I second that. What cartridge/inhaler issue? www.ajmc.com/journals/evidence-based-diabetes-management/2016/september-2016/patients-report-barriers-to-getting-afrezza-but-a1c-results-are-worth-it/P-1
"Kevin Michelizzi thought there must be some mistake. His doctor gave him some Afrezza samples from Sanofi. In an interview, Michelizzi described opening the first box, then a second, then a third. The cartridges were there, but “none of them had an inhaler.”...
...In a follow-up e-mail, Robinson said that the cartridges required refrigeration, while the inhalers did not, so this strategy saved refrigeration space.
“We’re stuck with that decision for the next few months,” said Castagna, who reluctantly confirmed the sample configuration. MannKind is retrofitting the manufacturing process so the sample will be in a single box by November, he said."
|
|
|
|
Post by kball on Sept 19, 2016 8:44:55 GMT -5
Wow...just when you thought...
|
|
|
|
Post by peppy on Sept 19, 2016 8:52:32 GMT -5
I second that. What cartridge/inhaler issue? www.ajmc.com/journals/evidence-based-diabetes-management/2016/september-2016/patients-report-barriers-to-getting-afrezza-but-a1c-results-are-worth-it/P-1
"Kevin Michelizzi thought there must be some mistake. His doctor gave him some Afrezza samples from Sanofi. In an interview, Michelizzi described opening the first box, then a second, then a third. The cartridges were there, but “none of them had an inhaler.”...
...In a follow-up e-mail, Robinson said that the cartridges required refrigeration, while the inhalers did not, so this strategy saved refrigeration space.
“We’re stuck with that decision for the next few months,” said Castagna, who reluctantly confirmed the sample configuration. MannKind is retrofitting the manufacturing process so the sample will be in a single box by November, he said."
"His doctor gave him some Afrezza samples from Sanofi. In an interview, Michelizzi described opening the first box, then a second, then a third. The cartridges were there, but “none of them had an inhaler.”...
sounds like sabotage.
|
|
|
|
Post by slugworth008 on Sept 19, 2016 9:04:37 GMT -5
www.ajmc.com/journals/evidence-based-diabetes-management/2016/september-2016/patients-report-barriers-to-getting-afrezza-but-a1c-results-are-worth-it/P-1
"Kevin Michelizzi thought there must be some mistake. His doctor gave him some Afrezza samples from Sanofi. In an interview, Michelizzi described opening the first box, then a second, then a third. The cartridges were there, but “none of them had an inhaler.”...
...In a follow-up e-mail, Robinson said that the cartridges required refrigeration, while the inhalers did not, so this strategy saved refrigeration space.
“We’re stuck with that decision for the next few months,” said Castagna, who reluctantly confirmed the sample configuration. MannKind is retrofitting the manufacturing process so the sample will be in a single box by November, he said."
"His doctor gave him some Afrezza samples from Sanofi. In an interview, Michelizzi described opening the first box, then a second, then a third. The cartridges were there, but “none of them had an inhaler.”...
sounds like sabotage.
Sure as hell sounds like sabotage in my book. |
|
|
|
Post by kbrion77 on Sept 19, 2016 9:20:04 GMT -5
www.ajmc.com/journals/evidence-based-diabetes-management/2016/september-2016/patients-report-barriers-to-getting-afrezza-but-a1c-results-are-worth-it/P-1
"Kevin Michelizzi thought there must be some mistake. His doctor gave him some Afrezza samples from Sanofi. In an interview, Michelizzi described opening the first box, then a second, then a third. The cartridges were there, but “none of them had an inhaler.”...
...In a follow-up e-mail, Robinson said that the cartridges required refrigeration, while the inhalers did not, so this strategy saved refrigeration space.
“We’re stuck with that decision for the next few months,” said Castagna, who reluctantly confirmed the sample configuration. MannKind is retrofitting the manufacturing process so the sample will be in a single box by November, he said."
"His doctor gave him some Afrezza samples from Sanofi. In an interview, Michelizzi described opening the first box, then a second, then a third. The cartridges were there, but “none of them had an inhaler.”...
sounds like sabotage.
Sabotage, huh? Sounds more like extremely poor planning between both Sanofi and Mannkind. |
|
|
|
Post by peppy on Sept 19, 2016 9:28:47 GMT -5
"His doctor gave him some Afrezza samples from Sanofi. In an interview, Michelizzi described opening the first box, then a second, then a third. The cartridges were there, but “none of them had an inhaler.”...
sounds like sabotage.
Sabotage, huh? Sounds more like extremely poor planning between both Sanofi and Mannkind. Quote: Sabotage, huh? Sounds more like extremely poor planning between both Sanofi and Mannkind.
reply: eu·phe·mism
noun
noun: euphemism; plural noun: euphemisms
a mild or indirect word or expression substituted for one considered to be too harsh or blunt when referring to something unpleasant or embarrassing.
"“downsizing” as a euphemism for cuts"
synonyms: polite term, indirect term, circumlocution, substitute, alternative, understatement, genteelism
"'influential person' is the local euphemism for underworld don"
|
|
